Safety of transperineal 14‐core systematic prostate biopsy in diabetic men

Objectives: To examine whether the transrectal ultrasound‐guided transperineal 14‐core prostate biopsy can be carried out safely in diabetic men and to determine adequate antimicrobial prophylaxis protocol in this setting. Methods: The present study included 539 men, 135 with concurrent diabetes mellitus (DM) and 404 without DM, who underwent transperineal extended 14‐core biopsy due to elevated prostate‐specific antigen ≥2.5 ng/mL and/or abnormal digital rectal examination. Any complication requiring prolonged hospitalization or rehospitalization during the 4‐week post‐biopsy period was considered major. All other complications were considered minor. Intensity of antimicrobial prophylaxis was prospectively reduced in a stepwise manner down to single dose of oral levofloxacin. Results: Except for DM, there was no significant difference in clinical background between the diabetic and non‐diabetic men. The procedure was completed in all revealing prostate cancer in 42% of the diabetic men and 36% of the non‐diabetic men (P = 0.23). Incidence of minor or major complications was not significantly different between the two groups. Minor complications were observed in 15.6% and 16.6% of each group, respectively, with voiding disturbance being the most common. No infectious major complication was observed regardless of the presence of DM. In the diabetic men, there was no statistical difference in incidence of biopsy‐related complications according to modality of DM treatment, HbA1c level or antimicrobial prophylaxis protocol. Conclusions: Transperineal 14‐core biopsy can be carried out without major infectious complications in diabetic men. Oral levofloxacin 300 mg once before the procedure seems to represent an effective antimicrobial prophylaxis in diabetic men without other risk of infection.